Biotest AG: Publication of the offer document on the voluntary public tender for Biotest AG by CREAT Group
PRESS RELEASEPublication of the offer document on the voluntary public tender for Biotest AG by CREAT Group
- Offer document reaffirms the offer announced on April 7, 2017
- The Management Board and the Supervisory Board welcome and support the offer
- The Management Board and the Supervisory Board will carefully review the offer document and issue a reasoned opinion pursuant to Section 27 WpÜG.
- The acceptance period will run from May 18, 2017, and is expected to end on June 15, 2017
Dreieich, 18 May 2017. Tiancheng (Germany) Pharmaceutical Holdings AG, the acquiring company of CREAT Group, today published the offer document on the voluntary public tender for all outstanding shares of Biotest AG. As announced on April 7, 2017, Tiancheng (Germany) Pharmaceutical Holdings AG is offering 28.50 Euro per Biotest ordinary share and 19.00 Euro per Biotest preference share.
The Management Board and the Supervisory Board will review the offer document carefully, bearing in mind the Company's best interests, and issue a reasoned opinion on the offer pursuant to Section 27 of the German Securities Acquisition and Transfer Act (WpÜG). Both boards welcome and support the offer.
Today's publication of the offer document marks the start of the acceptance period, which is expected to end on June 15, 2017.
About Biotest Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.
IR contact Dr. Monika Buttkereit phone: +49-6103-801-4406 email: firstname.lastname@example.org
PR contact Dirk Neumüller phone: +49-6103-801-269 email: email@example.com Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201 Preference shares: securities' ID No. 522723; ISIN DE0005227235 Listing: Prime Standard Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart
Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
18.05.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English
Company: Biotest AG Landsteinerstraße 5 63303 Dreieich
Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: firstname.lastname@example.org Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service